• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days.

作者信息

Coletto Lavinia Agra, Favalli Ennio Giulio, Caporali Roberto

机构信息

Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy.

Department of Clinical Rheumatology, ASST G. Pini & CTO, Milan, Italy.

出版信息

Dermatol Ther. 2020 Jul;33(4):e13415. doi: 10.1111/dth.13415. Epub 2020 May 2.

DOI:10.1111/dth.13415
PMID:32291828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7235523/
Abstract
摘要

相似文献

1
Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days.银屑病和银屑病关节炎：在新冠疫情期间如何管理免疫抑制剂
Dermatol Ther. 2020 Jul;33(4):e13415. doi: 10.1111/dth.13415. Epub 2020 May 2.
2
Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".关于《COVID-19与银屑病：是时候限制免疫抑制剂治疗了吗？行动呼吁》的评论
Dermatol Ther. 2020 Jul;33(4):e13360. doi: 10.1111/dth.13360. Epub 2020 Apr 16.
3
Reply to: "COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".回复：“2019冠状病毒病、梅毒与银屑病和银屑病关节炎的生物疗法：一则警示”
J Am Acad Dermatol. 2020 Jun;82(6):e215. doi: 10.1016/j.jaad.2020.03.103. Epub 2020 Apr 10.
4
COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.新型冠状病毒肺炎、梅毒与银屑病及银屑病关节炎的生物治疗：一则警示
J Am Acad Dermatol. 2020 Jun;82(6):e213. doi: 10.1016/j.jaad.2020.03.079. Epub 2020 Apr 1.
5
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.一名患有银屑病和银屑病关节炎的患者在使用阿达木单抗治疗期间COVID-19感染的非复杂病程。
Dermatol Ther. 2020 Jul;33(4):e13708. doi: 10.1111/dth.13708. Epub 2020 Jun 26.
6
Biologic therapy for psoriasis during the COVID-19 outbreak: The choice is to weigh risks and benefits.2019冠状病毒病疫情期间银屑病的生物治疗：选择需权衡风险与获益。
Dermatol Ther. 2020 Jul;33(4):e13490. doi: 10.1111/dth.13490. Epub 2020 May 20.
7
A challenging case of psoriasis flare-up after COVID-19 infection.1例新型冠状病毒肺炎感染后银屑病病情加重的疑难病例。
J Dermatolog Treat. 2020 Aug;31(5):448-449. doi: 10.1080/09546634.2020.1764904. Epub 2020 May 15.
8
Biologics for psoriasis in COVID-19 era: What do we know?新冠疫情时代用于治疗银屑病的生物制剂：我们了解什么？
Dermatol Ther. 2020 Jul;33(4):e13467. doi: 10.1111/dth.13467. Epub 2020 Jun 15.
9
COVID-19 in an elderly patient treated with secukinumab.一位接受司库奇尤单抗治疗的老年患者的新型冠状病毒肺炎
Dermatol Ther. 2020 Jul;33(4):e13580. doi: 10.1111/dth.13580. Epub 2020 May 27.
10
Antipsoriatic treatments during COVID-19 outbreak.新冠疫情期间的银屑病治疗
Dermatol Ther. 2020 Jul;33(4):e13345. doi: 10.1111/dth.13345. Epub 2020 Apr 10.

引用本文的文献

1
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.风湿肌肉骨骼疾病的免疫抑制剂治疗不会抑制对 SARS-CoV-2 感染的体液反应，并保留效应免疫细胞群体。
Front Immunol. 2022 Jun 10;13:873195. doi: 10.3389/fimmu.2022.873195. eCollection 2022.
2
Telemedicine in the Management of Patients with Rheumatic Disease during COVID-19 Pandemic: Incidence of Psychiatric Disorders and Fibromyalgia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis.COVID-19大流行期间风湿性疾病患者管理中的远程医疗：类风湿关节炎和银屑病关节炎患者精神障碍及纤维肌痛的发病率
Int J Environ Res Public Health. 2022 Mar 8;19(6):3161. doi: 10.3390/ijerph19063161.
3
What Has Changed in the Treatment of Psoriatic Arthritis After COVID-19?新冠疫情后银屑病关节炎的治疗有哪些变化？
Eurasian J Med. 2021 Jun;53(2):132-136. doi: 10.5152/eurasianjmed.2021.20222.
4
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
5
Biologics for Psoriasis during the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
J Clin Med. 2021 Mar 30;10(7):1390. doi: 10.3390/jcm10071390.
6
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis.糖皮质激素和免疫抑制疗法对慢性炎症性关节炎患者大队列中症状性 SARS-CoV-2 感染的影响。
Arthritis Res Ther. 2020 Dec 30;22(1):290. doi: 10.1186/s13075-020-02395-6.
7
Management of Patients With Inflammatory Rheumatic Diseases: Telemedicine and Rheumatologists Challenged in the Era of COVID-19.炎症性风湿疾病患者的管理：远程医疗与风湿科医生在新冠疫情时代面临的挑战
Front Public Health. 2020 Nov 9;8:558838. doi: 10.3389/fpubh.2020.558838. eCollection 2020.
8
Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.免疫抑制剂在冠状病毒大流行期间治疗免疫介导的炎症性疾病的效果。
Dermatol Ther. 2020 Nov;33(6):e14204. doi: 10.1111/dth.14204. Epub 2020 Sep 14.
9
Psoriasis and COVID-19: A narrative review with treatment considerations.银屑病与 COVID-19：一篇附有治疗考虑因素的叙述性综述。
Dermatol Ther. 2020 Nov;33(6):e13858. doi: 10.1111/dth.13858. Epub 2020 Jul 9.

本文引用的文献

1
COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.新型冠状病毒肺炎与银屑病：是时候限制免疫抑制剂的使用了吗？呼吁采取行动。
Dermatol Ther. 2020 Jul;33(4):e13298. doi: 10.1111/dth.13298. Epub 2020 Mar 22.
2
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
3
The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts.银屑病和银屑病关节炎感染的发生率及预测因素：纵向观察队列研究结果
J Rheumatol. 2016 Feb;43(2):362-6. doi: 10.3899/jrheum.140067. Epub 2016 Jan 15.
4
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).银屑病的生物制剂和系统治疗的严重感染风险：来自银屑病纵向评估和登记研究（PSOLAR）的结果。
JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718.
5
Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study.银屑病关节炎、银屑病和类风湿关节炎的糖尿病发病率：一项英国基于人群的队列研究。
Rheumatology (Oxford). 2014 Feb;53(2):346-52. doi: 10.1093/rheumatology/ket343. Epub 2013 Oct 31.
6
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.与类风湿关节炎相关的感染风险，及其合并症和治疗。
Rheumatology (Oxford). 2013 Jan;52(1):53-61. doi: 10.1093/rheumatology/kes305. Epub 2012 Nov 28.